Unlocking Growth Potential: Exelixis’ Cabometyx Leads Revenue as Zanzalintinib Emerges as Future Engine
Exelixis’s Cabometyx Driving Revenue Growth and Outlook for 2024 Expanding Oncology Portfolio and Shareholder-Friendly Initiatives Exelixis recently announced that their flagship drug, Cabometyx, continues to drive revenue growth, leading to a raised 2024 revenue forecast of $2.15–$2.2 billion. This positive news comes as the company plans to diversify its oncology portfolio by launching one new…